TNF and rheumatoid arthritis: Based on these advantages of Lox, Tof, MNs, and PDA, we fabricated a PT MN co-loaded with Lox and Tof, with the aim of combining different compositions and functionalities to achieve “all-in-one” therapeutic effects on RA, such as photo-responsive drug release, the MN-mediated permeation enhancement of Lox and Tof, site-directed therapy with the combination of Lox and Tof, and the inhibition of TNF-α (tumor necrosis factor α) and IL-1β (interleukin 1β) biomarkers via PTT.